Smac Mimetic Bypasses Apoptosis Resistance in FADD- or Caspase-8-deficient Cells by Priming for Tumor Necrosis Factor α-induced Necroptosis

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2011 Oct 27

PMID 22028622

Citations 52

Authors

Bram Laukens

Claudia Jennewein

Barbara Schenk

Nele Vanlangenakker

Alexander Schier

Silvia Cristofanon

Kerry Zobel

Kurt Deshayes

Domagoj Vucic

Irmela Jeremias

Mathieu J M Bertrand

Peter Vandenabeele

Simone Fulda

Affiliations

Soon will be listed here.

Abstract

Searching for new strategies to bypass apoptosis resistance, we investigated the potential of the Smac mimetic BV6 in Jurkat leukemia cells deficient in key molecules of the death receptor pathway. Here, we demonstrate for the first time that Smac mimetic primes apoptosis-resistant, FADD- or caspase-8-deficient leukemia cells for TNFα-induced necroptosis in a synergistic manner. In contrast to TNFα, Smac mimetic significantly enhances CD95-induced apoptosis in wild-type but not in FADD-deficient cells. Interestingly, Smac mimetic- and TNFα-mediated cell death occurs without characteristic features of apoptosis (i.e., caspase activation, DNA fragmentation) in FADD-deficient cells. By comparison, Smac mimetic and TNFα trigger activation of caspase-8, -9, and -3 and DNA fragmentation in wild-type cells. Consistently, the caspase inhibitor zVAD.fmk fails to block Smac mimetic- and TNFα-triggered cell death in FADD- or caspase-8-deficient cells, while it confers protection in wild-type cells. By comparison, necrostatin-1, an RIP1 kinase inhibitor, abolishes Smac mimetic- and TNFα-induced cell death in FADD- or caspase-8-deficient. Thus, Smac mimetic enhances TNFα-induced cell death in leukemia cells via two distinct pathways in a context-dependent manner: it primes apoptosis-resistant cells lacking FADD or caspase-8 to TNFα-induced, RIP1-dependent and caspase-independent necroptosis, whereas it sensitizes apoptosis-proficient cells to TNFα-mediated, caspase-dependent apoptosis. These findings have important implications for the therapeutic exploitation of necroptosis as an alternative cell death program to overcome apoptosis resistance.

Citing Articles

Smac/DIABLO protein acts as an independent prognostic factor in oral squamous cell carcinoma.

Franca Vieira E Silva F, Caponio V, Ballini A, Chamorro-Petronacci C, Lourenzo-Pouso A, Garcia-Garcia A Sci Rep. 2024; 14(1):30065.

PMID: 39627250 PMC: 11614858. DOI: 10.1038/s41598-024-76962-1.

Deregulation of New Cell Death Mechanisms in Leukemia.

Favale G, Donnarumma F, Capone V, Della Torre L, Beato A, Carannante D Cancers (Basel). 2024; 16(9).

PMID: 38730609 PMC: 11083363. DOI: 10.3390/cancers16091657.

SMAC Mimetics for the Treatment of Lung Carcinoma: Present Development and Future Prospects.

Pandey R, Bisht P, Wal P, Murti K, Ravichandiran V, Kumar N Mini Rev Med Chem. 2024; 24(14):1334-1352.

PMID: 38275029 DOI: 10.2174/0113895575269644231120104501.

Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics.

Pinto C, Slavic-Obradovic K, Furweger D, Thaler B, Souabni A, Carotta S iScience. 2023; 26(4):106381.

PMID: 37009211 PMC: 10064235. DOI: 10.1016/j.isci.2023.106381.

Bioluminescent RIPoptosome Assay for FADD/RIPK1 Interaction Based on Split Luciferase Assay in a Human Neuroblastoma Cell Line SH-SY5Y.

Ghanavatian P, Salehi-Sedeh H, Ataei F, Hosseinkhani S Biosensors (Basel). 2023; 13(2).

PMID: 36832063 PMC: 9954477. DOI: 10.3390/bios13020297.

References

Bonapace L, Bornhauser B, Schmitz M, Cario G, Ziegler U, Niggli F . Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010; 120(4):1310-23. PMC: 2846044. DOI: 10.1172/JCI39987. View

Varfolomeev E, Blankenship J, Wayson S, Fedorova A, Kayagaki N, Garg P . IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007; 131(4):669-81. DOI: 10.1016/j.cell.2007.10.030. View

Juo P, Woo M, Kuo C, Signorelli P, Biemann H, Hannun Y . FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ. 2000; 10(12):797-804. View

Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P . RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 2007; 14(3):400-10. DOI: 10.1038/sj.cdd.4402085. View

Vellanki S, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V . Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia. 2009; 11(8):743-52. PMC: 2713593. DOI: 10.1593/neo.09436. View

Kaiser W, Upton J, Long A, Livingston-Rosanoff D, Daley-Bauer L, Hakem R . RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011; 471(7338):368-72. PMC: 3060292. DOI: 10.1038/nature09857. View

Vince J, Wong W, Khan N, Feltham R, Chau D, Ahmed A . IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007; 131(4):682-93. DOI: 10.1016/j.cell.2007.10.037. View

High L, Szymanska B, Wilczynska-Kalak U, Barber N, OBrien R, Khaw S . The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2009; 77(3):483-94. DOI: 10.1124/mol.109.060780. View

Chang M, Jin W, Sun S . Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol. 2009; 10(10):1089-95. PMC: 2748822. DOI: 10.1038/ni.1777. View

10.

Varfolomeev E, Goncharov T, Fedorova A, Dynek J, Zobel K, Deshayes K . c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008; 283(36):24295-9. PMC: 3259840. DOI: 10.1074/jbc.C800128200. View

11.

Lockshin R, Zakeri Z . Cell death in health and disease. J Cell Mol Med. 2007; 11(6):1214-24. PMC: 4401285. DOI: 10.1111/j.1582-4934.2007.00150.x. View

12.

Kawahara A, Ohsawa Y, Matsumura H, Uchiyama Y, Nagata S . Caspase-independent cell killing by Fas-associated protein with death domain. J Cell Biol. 1998; 143(5):1353-60. PMC: 2133085. DOI: 10.1083/jcb.143.5.1353. View

13.

Fulda S . Tumor resistance to apoptosis. Int J Cancer. 2008; 124(3):511-5. DOI: 10.1002/ijc.24064. View

14.

Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87(1):99-163. DOI: 10.1152/physrev.00013.2006. View

15.

Ashkenazi A . Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008; 19(3-4):325-31. DOI: 10.1016/j.cytogfr.2008.04.001. View

16.

Geserick P, Hupe M, Moulin M, Wong W, Feoktistova M, Kellert B . Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol. 2009; 187(7):1037-54. PMC: 2806279. DOI: 10.1083/jcb.200904158. View

17.

Zhang H, Zhou X, McQuade T, Li J, Chan F, Zhang J . Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature. 2011; 471(7338):373-6. PMC: 3072026. DOI: 10.1038/nature09878. View

18.

Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S . Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2001; 1(6):489-95. DOI: 10.1038/82732. View

19.

Wang L, Du F, Wang X . TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008; 133(4):693-703. DOI: 10.1016/j.cell.2008.03.036. View

20.

LaCasse E, Mahoney D, Cheung H, Plenchette S, Baird S, Korneluk R . IAP-targeted therapies for cancer. Oncogene. 2008; 27(48):6252-75. DOI: 10.1038/onc.2008.302. View